This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
[ad_1] JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from
Read More[ad_1] JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from
Read More[ad_1] Here are the biggest calls on Wall Street on Monday: UBS reiterates Amazon as buy UBS is bullish heading
Read More